Perigon Wealth Management LLC grew its stake in Amgen, Inc. (NASDAQ:AMGN) by 4.0% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,083 shares of the medical research company’s stock after buying an additional 80 shares during the quarter. Perigon Wealth Management LLC’s holdings in Amgen were worth $384,000 at the end of the most recent reporting period.

Other institutional investors also recently added to or reduced their stakes in the company. Arbor Wealth Management LLC boosted its holdings in shares of Amgen by 154.5% in the second quarter. Arbor Wealth Management LLC now owns 168 shares of the medical research company’s stock valued at $31,000 after buying an additional 102 shares during the period. C J Advisory Inc acquired a new position in Amgen during the first quarter worth $40,000. Clarfeld Financial Advisors LLC acquired a new position in Amgen during the fourth quarter worth $41,000. Ashburton Jersey Ltd acquired a new position in Amgen during the second quarter worth $42,000. Finally, Sound Income Strategies LLC boosted its holdings in Amgen by 402.1% during the second quarter. Sound Income Strategies LLC now owns 236 shares of the medical research company’s stock worth $43,000 after purchasing an additional 189 shares during the last quarter. Institutional investors own 78.01% of the company’s stock.

Several brokerages recently commented on AMGN. Cowen restated a “buy” rating and set a $229.00 target price on shares of Amgen in a report on Wednesday, May 1st. Evercore ISI restated a “hold” rating on shares of Amgen in a report on Sunday, August 11th. BMO Capital Markets set a $230.00 target price on shares of Amgen and gave the stock a “buy” rating in a report on Wednesday, July 31st. Morgan Stanley reduced their target price on shares of Amgen from $211.00 to $207.00 and set an “overweight” rating for the company in a report on Monday, July 15th. Finally, Mizuho cut shares of Amgen from a “buy” rating to a “neutral” rating and increased their target price for the stock from $208.00 to $212.00 in a report on Monday. They noted that the move was a valuation call. Ten analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Amgen has a consensus rating of “Buy” and a consensus target price of $212.94.

In other news, Director R Sanders Williams sold 425 shares of the stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $183.04, for a total value of $77,792.00. Following the transaction, the director now directly owns 16,336 shares of the company’s stock, valued at $2,990,141.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ronald D. Sugar sold 2,000 shares of the stock in a transaction dated Wednesday, July 3rd. The shares were sold at an average price of $187.58, for a total transaction of $375,160.00. Following the completion of the transaction, the director now directly owns 16,336 shares in the company, valued at $3,064,306.88. The disclosure for this sale can be found here. In the last quarter, insiders sold 4,425 shares of company stock valued at $804,312. Corporate insiders own 0.25% of the company’s stock.

AMGN stock traded up $1.49 during trading hours on Wednesday, reaching $204.66. The stock had a trading volume of 499,073 shares, compared to its average volume of 3,882,518. The stock has a market capitalization of $122.35 billion, a PE ratio of 14.21, a price-to-earnings-growth ratio of 2.39 and a beta of 1.19. The company has a debt-to-equity ratio of 2.58, a current ratio of 2.89 and a quick ratio of 2.60. The stock has a 50-day simple moving average of $185.49 and a 200 day simple moving average of $183.23. Amgen, Inc. has a fifty-two week low of $166.30 and a fifty-two week high of $211.90.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, July 30th. The medical research company reported $3.97 EPS for the quarter, beating analysts’ consensus estimates of $3.58 by $0.39. The firm had revenue of $5.87 billion during the quarter, compared to analysts’ expectations of $5.67 billion. Amgen had a net margin of 33.78% and a return on equity of 76.17%. The company’s revenue for the quarter was down 3.1% compared to the same quarter last year. During the same quarter last year, the company posted $3.83 earnings per share. On average, sell-side analysts forecast that Amgen, Inc. will post 14.25 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, September 6th. Shareholders of record on Thursday, August 15th will be paid a $1.45 dividend. This represents a $5.80 dividend on an annualized basis and a yield of 2.83%. The ex-dividend date is Wednesday, August 14th. Amgen’s dividend payout ratio is currently 40.28%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Featured Story: What is the downside to momentum investing?

Want to see what other hedge funds are holding AMGN? Visit to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with's FREE daily email newsletter.